Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharma-Bio ServPBSV -27.16%43 5-Year RORE % is -235.90 as of Apr. 2026. GuruFocus rates PBSV with a GF Score™ of 43/100 and a GF Value™ of $0.58 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 504 Healthcare Providers & Services companies, Pharma-Bio Serv ranks worse than 97.22% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Pharma-Bio Serv's 5-Year RORE % for the quarter that ended in Apr. 2026 was -235.90%.
The industry rank for Pharma-Bio Serv's 5-Year RORE % or its related term are showing as below:
PBSV's 5-Year RORE % is ranked worse than 97.22% of 504
companies
in the Healthcare Providers & Services industry
Industry Median: 2.295
vs PBSV: -235.90
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Pharma-Bio Serv 5-Year RORE % Related Terms
Pharma-Bio Serv 5-Year RORE % Historical Data
* Premium members only.
The historical data trend for Pharma-Bio Serv's 5-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PBSV vs MGRX, BFRG, VYND: 5-Year RORE % Comparison
For the Health Information Services subindustry, Pharma-Bio Serv's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharma-Bio Serv 5-Year RORE % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Pharma-Bio Serv's 5-Year RORE % distribution charts can be found below:
* The bar in red indicates where Pharma-Bio Serv's 5-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Apr. 2026 and 5-year before.
Pharma-Bio Serv (PBSV) has a 5-Year RORE % of -235.90 as of Apr. 2026. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on Pharma-Bio Serv and its competitors. According to the industry distribution chart, Pharma-Bio Serv ranks #490 out of 504 companies in the Healthcare Providers & Services industry, placing it in the top 97.2%.
Is Pharma-Bio Serv's 5-Year RORE % too high?
Pharma-Bio Serv's current 5-Year RORE % is -235.90. Based on the distribution chart, Pharma-Bio Serv ranks #490 out of 504 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Pharma-Bio Serv has a GF Score™ of 43/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharma-Bio Serv's 5-Year RORE % compare to MGRX and BFRG?
According to the Healthcare Providers & Services industry distribution chart, Pharma-Bio Serv ranks #490 out of 504 companies for 5-Year RORE %. This places Pharma-Bio Serv in the lower half of its industry. The industry median 5-Year RORE % is 2.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year RORE % for a Healthcare Providers & Services company?
The median 5-Year RORE % among Healthcare Providers & Services companies is 2.30, based on 504 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year RORE % mean?
A high 5-Year RORE % can signal that a stock is expensive relative to its fundamentals. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on Pharma-Bio Serv and its competitors. For the Healthcare Providers & Services industry, the median 5-Year RORE % is 2.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharma-Bio Serv's current 5-Year RORE % is -235.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma-Bio Serv stock overvalued right now?
Based on GuruFocus' analysis, Pharma-Bio Serv (PBSV) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.58, compared to a current price of $0.42 — trading 27.2% below its estimated fair value. The current 5-Year RORE % is -235.90. Pharma-Bio Serv's overall GF Score™ is 43/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year RORE % calculated?
5-Year RORE % is calculated from a company's financial statements. For Pharma-Bio Serv (PBSV), the current 5-Year RORE % is -235.90 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharma-Bio Serv (PBSV) Overvalued in 2026?
Based on GuruFocus' analysis, Pharma-Bio Serv stock appears to be undervalued.
The current stock price of $0.42 is trading 27.2% below its estimated GF Value™ of $0.58.
GuruFocus considers Pharma-Bio Serv to be Modestly Undervalued.
Key valuation signals for PBSV:
5-Year RORE %: -235.90
GF Value™: $0.58 vs. price of $0.42 (27.2% below fair value)
No single metric tells the full story. See the PBSV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharma-Bio Serv Inc is a compliance and technology transfer services consulting firm. It also provides microbiological testing services and chemical testing services through its laboratory testing facility in Puerto Rico. It has three reportable segments: Puerto Rico technical compliance consulting which is the key revenue driver; United States technical compliance consulting; and Europe technical compliance consulting. The company offers solutions to the pharmaceutical, chemical, biotechnology, medical devices, cosmetic and food industries, and allied products companies. It generates maximum revenue from Puerto Rico and also has its presence in United States, Europe and Other countries.
43GF Score
Get the complete analysis for PBSV
5-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PBSV has been successfully added to your 
